Kidney health may change how obesity drug works in body

NCT ID NCT06352411

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a single injection of BI 456906, a drug being developed for obesity and liver disease, behaves in the blood of people with different levels of kidney function. Researchers will compare drug levels in 42 adults with normal kidneys to those with mild, moderate, or severe kidney problems. The goal is to see if kidney impairment changes how much drug gets into the bloodstream, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 456906 (survodutide)
What this could lead to: If successful, this study could help doctors understand how to dose BI 456906 safely for people with kidney problems.
What could go wrong: This is an early-phase study with only 42 participants, so results may not apply to everyone. It focuses on drug levels, not on treating disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY RENAL IMPAIRMENT

Contacts and locations

Locations

CRS Clinical Research Services Kiel GmbH

Kiel, 24105, Germany
CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.